{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T13:11:53Z","timestamp":1758633113368},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2001,4,1]],"date-time":"2001-04-01T00:00:00Z","timestamp":986083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6855,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,4]]},"DOI":"10.1023\/a:1011181016401","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T03:43:03Z","timestamp":1040614983000},"page":"457-462","source":"Crossref","is-referenced-by-count":15,"title":["Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin\u2019s lymphoma"],"prefix":"10.1016","volume":"12","author":[{"given":"A.","family":"Tulpule","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.U.","family":"Rarick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Kolitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.A.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.M.","family":"Espina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Letzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.R.","family":"Justice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Boswell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1011181016401_bb0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1200\/JCO.1985.3.3.299","article-title":"The low-grade non-Hodgkin\u2019s lymphomas Challenges and opportunities","volume":"3","author":"Rosenberg","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011181016401_bb0015","first-page":"75","article-title":"Natural history of the therapy for the indolent non-Hodgkin\u2019s lymphomas","volume":"20","author":"Horning","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011181016401_bb0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bmj.1.6112.533","article-title":"Comparison of combined and single-agent chemotherapy in non-Hodgkin\u2019s lymphoma of favorable histologic type","volume":"1","author":"Lister","year":"1978","journal-title":"BMJ"},{"key":"10.1023\/A:1011181016401_bb0025","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1182\/blood.V58.3.592.592","article-title":"The treatment of advanced stage favorable non-Hodgkin\u2019s lymphomas A preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation","volume":"58","author":"Hoppe","year":"1981","journal-title":"Blood"},{"key":"10.1023\/A:1011181016401_bb0030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0006-2952(78)90252-6","article-title":"Pharmacokinetics of liposome-encapsulated antitumor drugs","volume":"27","author":"Juliano","year":"1978","journal-title":"Biochem Pharm"},{"key":"10.1023\/A:1011181016401_bb0035","first-page":"3255","article-title":"Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors","volume":"52","author":"Forrsen","year":"1992","journal-title":"Cancer Res"},{"key":"10.1023\/A:1011181016401_bb0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00874439","article-title":"Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome)","volume":"12","author":"Guaglianone","year":"1994","journal-title":"Invest New Drug"},{"issue":"4","key":"10.1023\/A:1011181016401_bb0045","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1200\/JCO.1995.13.4.996","article-title":"Phase I\u2013II clinical and pharmacokinetic evaluation of liposomal daunorubicin","volume":"13","author":"Gill","year":"1995","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1023\/A:1011181016401_bb0050","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","article-title":"Randomized phase III trial of liposomal daunorubicin (DaunoXome) versus doxorubicin, bleomycin, vincristine (ABV) in AIDS-related Kaposi\u2019s sarcoma","volume":"14","author":"Gill","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011181016401_bb0055","first-page":"5a","article-title":"Phase I study of liposomal daunorubicin (LD) in refractory or relapsed acute myeloid leukemia (AML) or blast phase chronic myelogenous leukemia (CML-BP)","volume":"17","author":"Cortes","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 1","key":"10.1023\/A:1011181016401_bb0060","first-page":"233a","article-title":"A phase I trial of liposomal daunorubicin (DaunoXome) administered with high dose cytarabine (HiDAC) to patients with relapsed acute leukemia","volume":"92","author":"Cripe","year":"1998","journal-title":"Blood"},{"key":"10.1023\/A:1011181016401_bb0065","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.1023\/A:1011181016401_bb0070","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","article-title":"National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas Summary and description of a Working Formulation for clinical usage","volume":"49","author":"The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project","year":"1982","journal-title":"Cancer"},{"key":"10.1023\/A:1011181016401_bb0075","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A Revised European\u2013American classification of lymphoid neoplasms A proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1023\/A:1011181016401_bb0080","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","volume":"89","author":"The non-Hodgkin\u2019s lymphoma classification project","year":"1997","journal-title":"Blood"},{"key":"10.1023\/A:1011181016401_bb0085","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075","article-title":"A clinical analysis of two indolent lymphoma entities Mantle-cell lymphoma and marginal zone lymphoma (including the mucosa associated lymphoid tissue and monocytoid B-cell subcategories) A Southwest Oncology Group study","volume":"85","author":"Fisher","year":"1995","journal-title":"Blood"},{"key":"10.1023\/A:1011181016401_bb0090","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"for the non-Hodgkin\u2019s lymphoma classification project New approaches to classifying non-Hodgkin\u2019s lymphomas Clinical features of the major histologic subtypes","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1023\/A:1011181016401_bb0095","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","article-title":"Phase II trial of fludarabine phosphate in lymphoma An effective new agent in low-grade lymphoma","volume":"10","author":"Redman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011181016401_bb0100","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO.1994.12.4.788","article-title":"2-chloro-deoxyade-nosine is an active salvage therapy in advanced indolent non-Hodgkin\u2019s lymphoma","volume":"12","author":"Hoffman","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011181016401_bb0105","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2370::AID-CNCR17>3.0.CO;2-M","article-title":"Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin\u2019s lymphoma","volume":"83","author":"Tulpule","year":"1998","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1023\/A:1011181016401_bb0110","first-page":"11","article-title":"The treatment of indolent lymphomas Watchful waiting versus aggressive combined modality treatment","volume":"25","author":"Young","year":"1988","journal-title":"Semin Hematol"},{"key":"10.1023\/A:1011181016401_bb0115","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011181016401_bb0120","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419540728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419540728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/4\/457\/19479062\/12-4-457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:02:40Z","timestamp":1582164160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419540728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2001,4]]}},"alternative-id":["S0923753419540728"],"URL":"https:\/\/doi.org\/10.1023\/a:1011181016401","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,4]]}}}